Introduction
Atherosclerosis is a major cause of coronary heart disease (CHD) and along with cardioembolism contributes significantly to ischaemic stroke (IS). The disease involves gradual accumulation of lipids and inflammatory cells encapsulated by fibrotic tissue in the intima of larger arteries [1] . Erosion or rupture of the fibrous cap covering the atherosclerotic plaque exposes plaque content to circulating blood and triggers thrombosis that may lead to myocardial infarction (MI) and stroke. The more recent view of plaque rupture and erosion suggests that atherosclerotic lesions undergo circles of remodelling, involving both stabilization and destabilization events, rather than being gradually weakened in a continuous manner [2] .
Plaque remodelling involves breakdown of extracellular matrix (ECM), which is a process partly controlled by matrix metalloproteinases (MMPs), a family of 20 secreted or membrane-associated endoproteinases and their inhibitors [3, 4] . Evidence for a role of MMPs in cardiovascular disease (CVD) has been obtained from studies in transgenic disease models and in studies investigating some MMPs as biomarkers for clinical events [5] [6] [7] [8] [9] [10] . In contrast, few studies have evaluated the role of MMPs in CVD using human genetics integrated with mRNA and protein expression in carotid tissue. Robust genetic association between the MMP gene cluster (chromosome 11q22.3) and large-artery stroke was recently demonstrated in genome-wide association study (GWAS) [11] . In addition, association between SNPs at the 11q22.3 locus and COPD has been demonstrated [12] [13] . The lead SNP for large-artery stroke, rs660599, is located near the MMP12 gene, and it was shown that the MMP12 mRNA expression in disease tissue is increased compared to healthy controls, which suggested that MMP12 drives the genetic association signal for stroke observed at 11q22.3 [11] .
It is well established that identification of the causal gene of GWAS loci is challenging, mainly due to high degree of linkage disequilibrium across large regions of the genome but also because distal genomic regulation of genes is common. The 11q22.3 region is no exception as it harbours several other members of the MMP family (MMP7, MMP20, MMP8, MMP10, MMP1, MMP3 and MMP13), of which many have been suggested to play a role in atherosclerosis. Therefore, additional evidence is required to establish the role of MMP12 in large-artery stroke. To address this question, we applied an integrative approach and investigated MMP12 protein and gene variants in relation to carotid intima-media thickness (cIMT) progression, incident CVD, transcriptomic and proteomic levels in carotid plaque tissue, followed up with detailed in situ and in vitro studies (design shown in Fig. 1 ).
Materials and methods

The IMPROVE study
The IMPROVE study is a multicentre, longitudinal, observational study, which recruited 3711 subjects with at least three cardiovascular risk factors but who were asymptomatic for CVD. Subjects were recruited from Finland, France, Italy, the Netherlands and Sweden. Detailed cIMT measurements were performed at baseline, after 15 months and at 30 months. The Fastest-IMT max-progr parameter, herein referred to as cIMT progression, was previously developed and evaluated in the IMPROVE study and found to independently predict new CVD events [14] . Incident CVD end-points were defined as occurrence of myocardial infarction, angioplasty, diagnosis of angina pectoris, angioplasty, coronary artery bypass grafting and/or sudden cardiac death, ischaemic stroke, transient ischaemic attack, peripheral revascularization and/or diagnosis of intermittent claudication during a median followup of 36 months. Further design features and definitions of the study are described in the online supplement and in previously published articles [14, 15] . Plasma MMP12 concentrations were measured at baseline using the Olink ProSeek CVD array I (Olink Proteomics, Uppsala, Sweden), according to the standard protocol [16] . The interplate coefficient of variation for the MMP12 assay was 14%, as estimated using a pooled plasma control across all plates. The measurements were carried out in 3394 IMPROVE participants in whom genotype information postquality control (QC) was also present. Plasma MMP12 activity was measured in duplicates in 20 plasma samples from the IMPROVE cohort. Ten samples were randomly chosen from the 75th to 95th percentile of plasma MMP12 concentration and ten from the 5th to 25th percentile. Activity was measured with the Fluorimetric Sensolyte 520 MMP12 Assay Kit (Anaspec), which specifically detects elastin degradation products (desmosine).
Genotyping in the IMPROVE study was performed using the Illumina CardioMetabochip and the Immunochip arrays [17, 18] . The combined SNP genotyping data on both platforms were merged and subjected to the following QC using PLINK 1.7, standard programming tools and manual proofreading. SNPs were excluded for probe to genome mismatch, incorrect assignment of allelic variants in the array design, failed Hardy-Weinberg equilibrium test at 1 9 10 À6 , call rate <95% or failed Illumina genotype calling QC. Samples were excluded that showed evidence of gender mismatch, abnormal inbreeding coefficient, failed cryptic relatedness test or had an overall sample call rate <95%. After QC and filtering out of SNPs with a minor allele frequency of <0.5%, a total number of 260 484 unique SNPs in 3403 subjects remained for analysis.
The BiKE study
Patients undergoing surgery for symptomatic (S) or asymptomatic (AS), high-grade (>50% NASCET) carotid stenosis at the Department of Vascular Fig. 1 Flow chart of the study cohorts and design. Analyses of plasma MMP12 concentrations in relation to cIMT progression, future CVD events and SNPs were conducted in the IMPROVE study, which recruited 3397 subjects with high CVD risk but without manifest CVD at baseline. These investigations were followed by eQTL analyses of the associated SNPs in relation to MMP12 mRNA expression in atherosclerotic plaque specimens from 127 patients undergoing carotid endarterectomy in the BiKE study. Furthermore, MMP12 mRNA and protein expression levels were examined in atherosclerotic plaques compared to control tissues (nonatherosclerotic arteries or adjacent distal plaque tissue). Finally, MMP12 protein localization, activity and interaction with elastin and the effects of MMP12 silencing were investigated using molecular biology methods in plaques, plasma and functional assays in vitro.
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Surgery, Karolinska University Hospital, Sweden, were consecutively enrolled in the study and clinical data recorded on admission [19] . Symptoms of plaque instability were defined as transitory ischaemic attack (TIA), minor stroke (MS) and amaurosis fugax (retinal TIA; AF). Patients without qualifying symptoms within 6 months prior to surgery were categorized as AS and indication for carotid endarterectomy based on results from the Asymptomatic Carotid Surgery Trial (ACST) [20] . Carotid endarterectomies (carotid plaques, CP) and blood samples were collected at surgery and retained within the Biobank of Karolinska Endarterectomies (BiKE). This study involved three nonoverlapping subcohorts of patients, where one Affymetrix microarray data set was generated by profiling n = 127 atherosclerotic plaques (of which n = 87 were from S + 40 from AS patients) and n = 10 normal arteries (further referred to as the 'large data set') and the other by profiling n = 50 plaques (n = 40 from S + 10 from AS patients) and n = 5 normal arteries (further referred as the 'small data set'). DNA genotyping by Illumina chips was carried out on patients from the 'large' subcohort, and used for expression quantitative trait loci (eQTL) analyses. The third subcohort of n = 18 BiKE plaques (n = 9 from S + 9 from AS patients, matched for gender, age and statin medication) was analysed using LC-MS/MS as previously described [21] . For these proteomic analyses, a central portion of the plaque corresponding to the maximum stenosis was separated from the respective downstream peripheral end (adjacent tissue) of the plaque and used in comparisons [22, 23] . Details of patient demographics, sample processing, microarray and proteomic analyses have been described previously, and the study was approved by the regional Ethics Committee [24] [25] [26] [27] .
In this study, CHD [28] was defined as stable and unstable angina, nonfatal MI and coronary death and large-artery stroke as thrombosis or embolism due to atherosclerosis of a large artery (internal carotid-, middle cerebral-, vertebral-or basilar arteries) [29] . The study cohorts and workflow are presented in Fig. 1 .
Statistical analyses
Association between plasma MMP concentrations, SNPs and cIMT at baseline and progression (fastest-IMT max-progr ) and incident CVD was tested using linear or logistic regression models with one basic model adjusting for recruitment centre, age, gender and another advanced model including also Framingham risk score parameters, that is smoking, diabetes, systolic blood pressure, HDL-C and total cholesterol. Survival analysis of plasma MMP12 tertiles was performed using Cox-regression. A total number of 67 cerebrovascular and 130 coronary end-points were observed after 36 months in the subset of 3394 IMPROVE subjects with complete baseline clinical data, genetic information and plasma MMP12 measurements. A total of 260 484 SNPs from the combined Illumina Immunochip and Metabochip genotyping arrays were tested as determinants for plasma MMP12 using the Plink 1.9 Wald-test of residuals derived from a linear regression model that adjusted for recruitment centre, age, gender, smoking, diabetes, hypertension, BMI and Olink ProSeek analysis batch [30] . The standard P-value threshold for genome-wide significance at 5 9 10 À8 was used in the discovery of novel SNPs linked to plasma MMP12 concentrations. Microarray and proteomic data set analyses of BiKE samples were performed as reported previously [21, 24] . Correlation between mRNA or protein levels was assessed using Spearman, whereas ANOVA was used for multigroup comparisons, with P < 0.05 as threshold for statistical significance. In the in vitro studies, cells were automatically counted using the 'Cell Counter' plugin of the ImageJ software. Differences between the groups were tested using Student's t-test.
Additional methods are available in the Data S1.
Results
Plasma MMP12 levels associate with cIMT progression and incident cardiovascular events MMP12 plasma concentrations were positively correlated with age, smoking and diabetes and inversely with HDL-C in the IMPROVE study (Table 1) , whereas no or weak correlations were observed with gender, systolic blood pressure or total cholesterol. Plasma MMP12 at baseline was tested as potential predictor of cIMT both at baseline and in progression, using a basic model and an advanced model with additional adjustment for Framingham risk score baseline parameters. As previously shown by Goncalves et al. [10] , plasma MMP12 was associated with cIMT at baseline, with the average thickness across all measured segments showing the strongest association ( Table 2 ). The plasma MMP12 concentration was also positively associated with faster cIMT progression, which persisted after adjustment for Framingham score parameters ( Table 3 ). The association between plasma MMP12 concentration and cIMT progression persisted even after additional adjustment for IMT max at baseline (standardized beta = 0.052, P = 0.008). Plasma MMP12 levels were also associated with incident CVD at 36 months (n = 197) after adjustment for study site, age and gender (odds ratio 1.26, 95% confidence interval (1.03-1.55), P = 0.028). The odds ratio for cerebrovascular events (n = 67) was 1.45, 95% confidence interval (1.03-2.05), P = 0.034. After adjustment for Framingham risk score parameters, associations with both all CVD events and with cerebrovascular events only were attenuated (odds ratio 1.13, 95% confidence interval (0.91-1.40), P = 0.26 and odds ratio 1.25, 95% confidence interval (0.87-1.81), P = 0.22, respectively). A survival analysis of plasma MMP12 tertiles suggested that patients in the highest tertile progressed more rapidly to cerebrovascular end-points compared to the middle and lowest tertile (Cox-regression P = 0.022, Figure S1 ) After adjustment for covariates, the association was no longer significant (P = 0.15).
Of note, MMP1, MMP3, MMP7 and MMP10 (present on the Olink CVD I assay) were also tested for association with cIMT at baseline, cIMT progression and incident CV events, but did not pass significance levels.
SNPs at 11q22.3 and plasma MMP12 concentrations
Next, we aimed to assess whether SNPs at 11q22.3 were linked to plasma MMP12 concentration using the IMPROVE study. Of a total number of 260 484 SNPs, 12 SNPs exceeded the standard threshold for genome-wide significance at 5 9 10
À8 for association with plasma MMP12 concentration ( Figure S2 ). All associated variants mapped to the MMP gene cluster region on chromosome 11q22.3. SNP rs660599, previously associated with risk of stroke in the METASTROKE study by Traylor et al. [11] , was associated with plasma MMP12 at P = 8.8 9 10
À35 . To identify potential additional association signals at this locus, conditional analyses were performed by adding the lead variant as covariate in linear regression models of adjusted plasma MMP12. After three rounds of conditioning, including in order rs499459, rs1892971 and rs613804, no association signal at 5 9 10 À8 remained (Table S1 ). The r 2 measure for linkage disequilibrium (LD) was less than 0.01 for any combination of these SNPs, suggesting that the effects of rs499459, rs1892971 and rs613804 on plasma MMP12 concentration are independent from one another (Table S2) . Finally, for the three variants emerging from IMPROVE analyses (rs499459, rs1892971 and rs613804) and the one from the METASTROKE study (rs660599), we also stratified the association with plasma MMP12 levels, mean and max cIMT and plaque area by each allele (Table S3) . Interestingly, our results show that the A allele of rs660599, which was previously associated with stroke risk in the METASTROKE study, was associated with higher cIMT for the different intima-media measures; however, the same allele also associated with lower plasma MMP12 concentration. Similarly, the A allele of rs499459 was associated with higher cIMT and lower plasma MMP12 levels.
SNPs in the MMP12 region affect its mRNA expression in atherosclerotic plaque tissue
To evaluate potential associations of SNPs rs499459, rs613804 and rs1892971 with plaque MMP12 mRNA levels in patients with carotid atherosclerosis, eQTL analyses were performed using microarray data from the BiKE cohort. A tentative association was found for rs1892971 with MMP12 mRNA levels in plaques (P = 0.079) (Fig. 2a) . To investigate whether the effect of rs1892971 was specific for MMP12 or related also to adjacent genes in the MMP gene cluster, we tested its association with expression of MMP1, MMP3 and MMP13 in plaques, but no significance could be shown (Fig. 2a) . A proxy for rs499459 (rs566125, r 2 = 0.92; D' = 1) showed no association with MMP12 plaque expression in the whole cohort, but when the association was stratified according to the patient phenotype, this variant showed significance particularly in plaques from asymptomatic patients ( Figure S3 ). However, it was also significantly associated with expression of MMP1, MMP3 and marginally with MMP13 (P = 0.00048, P = 0.02 and P = 0.045, respectively, Fig. 2b ). No significance was obtained by similar eQTL analyses for rs613804. In addition, we sought to evaluate whether the reported lead SNP for large-artery atherosclerotic stroke, rs660599, was also related to MMP12 expression levels in plaques. A perfect proxy for rs660599 and rs615098 (
showed association with MMP12 mRNA expression in plaques generally (P = 0.0039), as well as in plaques from asymptomatic patients (P = 0.005) and symptomatic ones (P = 0.049) separately (Figure S3) . Interestingly, this variant also showed strong associations with both MMP1 and MMP3 levels in plaques (P = 0.0016 and P = 0.0025, respectively, Fig. 2c ). Other MMPs in this region (MMP7, MMP8, MMP10, MMP20 and MMP27) were also examined for association with these variants, but showed no significance.
Further analysis of LD in the associated genomic region using the SNIPA tool [31] with data from the European part of the 1000 genomes project showed that rs499459 is located in a broader region of high LD with multiple other SNPs (including the lead SNP for stroke rs660599) that span MMP1, MMP3 and MMP12. In contrast, rs613804 is located in a region of high LD near and some distance downstream of the MMP12 gene. SNP rs1892971 (and those in high LD) is located in a narrow intergenic region upstream of MMP12 and downstream of MMP13 ( Figure S4 ).
Of note, MMP12 mRNA expression levels found in plaques from these eQTL analyses were several fold higher than levels of any other interrogated MMP in this region.
MMP12 is highly elevated in carotid plaques from symptomatic patients Indeed, on the transcriptomic level, we observed strong upregulation of the MMP12 mRNA expression in two independent microarray data sets comparing plaques versus normal arteries (Fig. 3a) . In the large data set, the difference between these groups was log mean AE SD = 8.14 AE 0.17, P < 0.0001, whilst in the smaller data set, it was log mean AE SD = 5.20 AE 0.22, P < 0.0001. Further upregulation was noted by stratifying patients into symptomatic versus asymptomatic category (large data set log mean AE SD = 0.74 AE 0.33, P = 0.03), and a trend towards upregulation in symptomatic patients was noted also in the smaller data set (not shown). A strong enrichment of MMP12 was confirmed on the proteomic level, with mean difference AE SD = 0.90 AE 0.10, P = 0.04 comparing central plaques versus adjacent tissue and mean difference Fig. 2 eQTL analysis of MMP12 associated SNPs in atherosclerotic plaques. MMP12 variant rs1892971 was found to be tentatively associated with MMP12 mRNA expression in carotid plaques. This variant was also unassociated with the expression of other MMPs from the same locus in plaques (a). Variant rs566125 was strongly associated with the expression levels of MMP1 and marginally also MMP3 and MMP13, but not MMP12 (b). SNP rs615098 (a perfect proxy for METASTROKE MMP12 associated variant rs660599) was marginally associated with MMP12 expression in plaques, and significantly to the expression of both MMP1 and MMP3 (c). Plots show median AE standard deviation (SD).
AE SD = 1.00 AE 0.07, P = 0.03 by comparing plaques from symptomatic versus asymptomatic patients (Fig. 3a) .
To evaluate the previous publications reporting high expression of MMP12 in macrophages [32] [33] [34] [35] , we next investigated the correlation between MMP12 expression and macrophage cell markers in plaques (Fig. 3b) . MMP12 transcript was strongly significantly correlated with that of macrophage markers CD163 (Spearman r = 0.67, P < 0.0001), CD36 (r = 0.81, P < 0.0001) and MAC2 (r = 0.72, P < 0.0001), and similarly positive significant correlations of MMP12 with macrophage markers were confirmed on the protein level. 
MMP12 localizes to macrophages and interacts with elastin in plaques
In continuation, we sought to trace the MMP12 protein and its major substrate elastin in human carotid arteries by immunohistochemistry. No signal for MMP12 was present in a normal artery whereas elastin was abundantly expressed in the media, as expected (Fig. 4a, arrows) . In plaques, we localized total MMP12 mostly to macrophagerich regions in the necrotic core by costaining with an antibody against macrophage marker CD68 (Fig. 4b, third panel, arrows and Figure S5a) . We also detected preserved, orderly packed elastin fibres subintimally at the plaque periphery, where no MMP12 was expressed (Fig. 4b, second panel,  arrows) . However, towards the necrotic core, staining for elastin appeared gradually disarranged and colocalized with MMP12 (Fig. 4b, second panel,  enlarged inset) , and was lost in consecutive sections of areas near the fibrous cap with condensed MMP12 + macrophages ( Figure S5a , enlarged insets). Signal for active MMP12 was observed diffusely in the extracellular matrix in the lesions, where elastin fibres were disarranged or absent ( Figure S5b, arrows) . Furthermore, by proximity ligation assay (PLA), we showed that MMP12 and elastin proteins cointeract in plaques in situ, Fig. 4 Localization of MMP12 in plaques. In the normal artery, no MMP12 immunoreactivity was detected, whilst elastin (green signal) was abundant in the media (a, arrows). In consecutive plaque sections (b), MMP12 was localized to the CD68 + macrophage-rich regions in the necrotic core (third panel, arrows and enlarged inset). Intact elastin fibres were present at the periphery of the plaques (middle panel, green staining, arrows) where no MMP12 (red signal) was expressed, but they appeared gradually disarranged closer towards the necrotic core where MMP12 was enriched (enlarged inset). By proximity ligation assay (PLA) in consecutive plaque sections, positive signal for MMP12 and elastin cointeracting proteins was detected (enlarged inset, middle panel), specifically in regions with moderate to strong MMP12 expression (c). As positive control, PLA probe directed to MMP12 antibody was used, showing areas of intense MMP12 expression in the necrotic core (arrows, third panel). No PLA signal was observed in the negative control (enlarged inset, first panel). particularly in regions with moderate to strong MMP12 expression (Fig. 4c, enlarged insets) .
MMP12 levels correlate with elastin breakdown in plasma and plaques from atherosclerotic patients
We also assessed the relationship between MMP12 concentration and elastin degradation in plasma from the IMPROVE cohort, by measuring the level of the released degradation product desmosine. With equal elastin substrate amount available, we observed on average a 22% elevated elastin degradation in plasma samples with high MMP12 levels compared to those with low MMP12 levels (mean 56.1 AE 5.84 vs. 46.0 AE 9.20 lmol L À1 desmosine, P = 0.15, Figure S6a) . Similarly, in plaques, we observed a strongly significant inverse correlation between MMP12 and elastin protein levels (r = À0.47, P = 0.004, Figure S6b ). Together with immunostainings for active MMP12 in plaques, our results confirm an association between higher MMP12 levels and increased elastolytic activity both in plasma and plaques from atherosclerotic patients.
MMP12 silencing leads to reduced macrophage recruitment and ECM invasion capacity
In vitro experiments were performed to evaluate the previous studies suggesting that MMP12 influences macrophage migration and degradation of ECM proteins [34] . MMP12 mRNA expression in THP-1-derived human macrophages was effectively inhibited by siRNA, and the reduction was estimated to 70% by qPCR analysis ( Figure S7 ). Western blot demonstrated that MMP12 mRNA downregulation was associated with~25% reduction in active MMP12 protein in macrophages ( Figure S7 ). Our results showed that macrophages with reduced MMP12 levels exhibited~30% lower invasion capacity compared to controls (%inva-sion = 45 AE 13 vs. 64.5 AE 12, P = 0.01). We then examined the macrophage invasion capacity upon lowering of the MMP12 availability with an MMP12-specific antibody, in both the control and the silenced cells. MMP12 inhibition by antibody blocking resulted in~31% less macrophage invasion compared to controls (% invasion = 16.5 AE 4.2 vs. 23.9 AE 5.2, P = 0.04). Furthermore, we observed a reduction in the total number of macrophages invading through the ECM once the antibody was introduced. The mean reduction was 63%, P = 0.02, for cells with suppressed MMP12 levels and 62%, P = 0.02, for those with normal MMP12 levels (Fig. 5a ).
In addition, we sought to identify whether MMP12 expression levels in macrophages affected the recruitment of other macrophages. We observed that the migration of new macrophages was 20% lower towards macrophages with reduced MMP12 expression.
Postmigration, 28.5% (mean = 430.5 AE 27 cells) of the total cell count in the Transwell chamber originated from macrophages that migrated towards those with suppressed MMP12, whereas 35.4% (mean = 743.5 AE 81 cells) originated from the population of macrophages that had migrated towards those with unchanged MMP12 expression (P = 0.01, Fig. 5b ).
Discussion
We used an integrative approach based on genetics, transcriptomics and proteomics in clinical and experimental samples to demonstrate that i) MMP12 is regulated at the mRNA and protein level by SNPs in the MMP gene cluster, ii) its plasma concentration is linked to cIMT progression as well as cerebrovascular events in high-risk subjects and iii) it is highly enriched in human atherosclerotic plaques where it interacts with elastin and enhances macrophage invasion. Moreover, we link a SNP near MMP12 that was previously shown to be associated with stroke by Traylor et al. [11] with plasma MMP12 concentrations and mRNA expression of MMP12, but also with other MMPs in carotid plaques. Therefore, the present investigation in combination with the recent article by Traylor et al. suggests that MMP12 may be causally implicated in large-artery stroke.
We found that three SNPs, rs499459, rs613804 and rs1892971, which are all located in chromosome 11q22.3 region near the genes MMP1, MMP3, MMP12 and MMP13, were independently associated with plasma MMP12 concentration. No other signals at genome-wide significance were observed in our study, although we acknowledge that SNPs outside of chromosome 11q22.3 with smaller effects on plasma MMP12 may still exist. The finding links chromosome 11q22.3 to plasma MMP12, but does not provide conclusive evidence that the associations are mediated via the MMP12 gene itself, as other genes in the region may also play a role in determining the plasma MMP12 concentration. To further investigate whether the SNPs associated with plasma MMP12 levels were specifically involved in the regulation of MMP12 or had effects on neighbouring MMPs too, we Transwell, and cells were stained with the nuclear stain DAPI (blue). In (b), macrophage nuclei stained red (DRAQ5) represent the primary invaded cells in control or siMMP12 conditions, whilst macrophage nuclei in blue (DAPI) represent the migrated cells in both conditions. Purple-coloured nuclei are those double-stained for DRAQ5/DAPI. On average, 70% (AE16.2% SD, P = 0.011) more macrophages migrated towards the control macrophages than towards siMMP12 macrophages. The quantification is represented as a bar graph in the last panel.
performed eQTL analyses in carotid plaques. The results revealed that rs1892971 is marginally linked to MMP12 mRNA expression, whereas rs499459 is an eQTL also for MMP1 and MMP3. Based on the LD analysis and the eQTL results, one may speculate that rs1892971 is more distinctly related to the MMP12 gene, whereas rs499459 and SNPs in LD such as rs660599 may influence a broader set of MMPs in the region. Analysis also indicated that rs499459 and rs660599 variants may have the potential to highlight a subgroup of patients who are clinically silent at the time of surgery (asymptomatic), but that may confer a higher risk of stroke, based on association with MMP12 expression in their plaques.
In the IMPROVE study, we showed that increased plasma MMP12 concentration at baseline was robustly associated with baseline cIMT. This result is well in line with the previous report by Goncalves et al. In addition, we observed that plasma MMP12 at baseline predicted a higher rate of cIMT change over time, regardless of the baseline cIMT, and an increased risk of suffering a cerebrovascular event within 36 months from baseline. We noted that the association of plasma MMP12 with prospective CVD events was attenuated by adjustment for Framingham risk score parameters, which implies that MMP12 in plasma reflects the presence of one or several of the Framingham score risk factors. Indeed, positive correlations between plasma MMP12 and systolic blood pressure, high-density lipoprotein cholesterol (HDL-C) and low-density lipoprotein cholesterol (LDL-C) have previously been reported [10] , which limits the implications of the reported association of plasma MMP12 with cIMT progression for CHD. Importantly, as MMP12 concentrations measured with our plasma assay may not necessarily reflect the proteinase activity of MMP12, we addressed this issue by a complementary experiment where we confirmed that subjects with higher plasma MMP12 concentrations showed an overall higher concentration of the elastin degradation product desmosine.
We also assessed MMP12 expression in a large biobank of human carotid endarterectomy samples and found that it was strongly enriched at both transriptomic and proteomic levels in plaques compared to undiseased arteries, as well as in plaques from patients that suffered stroke compared to asymptomatic ones, which not only validates but also extends previous publications about MMP12 [32] . Regarding the proteomic enrichment of MMP12 in central vs. distal segments of plaques, these areas have been identified as areas of severe plaque complications vs. stable growth, respectively. It has been recognized that the central part is associated with all components of a complicated lesion (fibrous cap, necrotic core, shoulder region) and increases incidence of cap rupture, whilst the adjacent peripheral end is associated with higher SMC content and represents the fibrotic intima [36] [37] [38] . Taken together with our genetic data, these findings underscore the significance of MMP12 in prevalent as well as incident stroke.
Interestingly, Scholtes et al. earlier showed that patients having a high proportion of MMP12 expressing macrophages in their carotid plaques are more likely to suffer subsequent stroke and MI [33] . In this study, MMP12 protein was localized to macrophages and shown to interact with elastin in situ, especially in areas of degraded ECM. It has been previously demonstrated that MMP12 has broad substrate specificity for a range of ECM proteins, including type IV collagen, fibronectin, laminin, vitronectin and basement membrane proteins, whilst potential regulators of MMP12 in the atherosclerotic environment include several proatherosclerotic inflammatory cytokines and growth factors released by various cells in the atherosclerotic milieu, such as macrophages, smooth muscle and endothelial cells [39] . Considering that MMP12 activates MMP2 and MMP3 [40] , we suggest that besides direct effects, higher expression of MMP12 could also lead to activation of these other MMPs in plaques, which would further increase degradation of the fibrous cap and promote plaque instability. Considering that plaque rupture frequently occurs over a macrophage-rich area near the shoulder of the plaque [41] , it is interesting to hypothesize that macrophages expressing MMP12 may particularly contribute to thinning and rupture of the fibrous cap and subsequent adverse events. It is worth noting here that the BiKE cohort comprises only advanced lesions (AHA grade IV and V) and therefore cannot provide information about disease progression. Also, the phenotyping of patients based on the presence or absence of cerebral symptoms was likely insufficient to completely exclude overlap between symptomatic and asymptomatic groups, as lesions from asymptomatic patients may vary in morphological features of plaque instability [27] . In addition, as atherosclerosis presents different features in different vascular beds, we limit our findings about MMP12 to carotid arteries. Important studies that have helped to expand the understanding of MMP12 in atherosclerosis were published by Liang et al. [42] , who demonstrated that rabbits overexpressing human MMP12 in tissue macrophages developed more extensive atherosclerosis in large arteries compared to controls, and Johnson et al., who showed that a murine-specific MMP12 inhibitor significantly reduced atherosclerotic plaque area in Apo-E knockout mice, fed a Western diet [43] . The MMP12 inhibitor treatment induced additional beneficial changes, such as attenuated macrophage invasion and apoptosis. Our in vitro results support the notion that MMP12 influences macrophage invasion, as we were able to validate these previous studies by showing markedly decreased migration through the ECM upon MMP12 suppression [34] . Moreover, we demonstrated that MMP12 suppression not only attenuated macrophage invasion, but also reduced the recruitment of other macrophages. One may speculate that the invasion-promoting effects of MMP12 contribute to a vicious cycle where the rate of new macrophage recruitment into plaques is amplified by increased production of MMP12 in plaque macrophages and a systemic release of MMP12 to the circulation. Therefore, suppression of MMP12 could promote double protective effects on the progression of disease: in reducing the invasion capacity of macrophages and prohibiting further macrophage recruitment, as well as in ameliorating the overall inflammation. One limitation of our invasion assay with the secondary macrophage migration setup could be the degradation level of the ECM coating for the newly invading macrophages. This could be dependent not only on the primary macrophages in the culture (control or siMMP12), but also the number of the available cells. Thus, a less degraded ECM present in the control macrophage culture might provide an easier access for migration and affect the secondary invasion rate. However, these effects are likely to be reflective of the pathophysiological situation in plaques as well, and in vitro may be considered less significant due to the presence of potent chemo-attracting properties of the medium environment in the bottom well.
Altogether, in the present study, we show that MMP12 transcriptomic and proteomic levels are strongly significantly increased in plaques compared with control tissue and in plaques from symptomatic vs. asymptomatic patients. MMP12 localizes to CD68+ macrophages in plaques, where it interacts with elastin and its silencing results in reduced macrophage migration. These studies clearly link higher MMP12 mRNA and protein levels in plaques to increased atherosclerotic disease. In contrast, it appears that genetically lower plasma MMP12 is significantly associated with increased cIMT measurements and risk of stroke. Our study does not aim to disentangle this seemingly complex relationship, but one potential explanation we suggest is the locus pleiotropy, as it is possible that the MMP12 SNPs (in addition to plasma MMP12) are also associated with other yet unknown factors, which may be responsible for their observed protective effects. It may also be that MMP12 expression has differential effects during early atherogenesis compared to advanced stages, and even the differential local vs. systemic effects should be taken into account. We speculate that plasma MMP12 may have a protective function, which it can exert on the growing plaque in the vasculature by 'surveying' and minimizing the plaque deposits especially during early atherogenesis, whilst the MMP12 secreted by macrophages within the late stage plaques degrades the tissue rendering it more prone to rupture.
Despite encouraging preclinical data, the design and development of selective MMP inhibitors for therapeutic use in CVD still remain at an early stage. The failure of the first generation of broadspectrum inhibitors undermined continued evaluation of MMPs as disease targets, and the main focus recently has been to design inhibitors targeting detrimental MMPs, without interfering with those that have an important role in preventing the progression of disease [44] . To achieve this, a greater understanding of the general MMP functions remains essential, including potential differences in how MMP12 particularly contributes to carotid vs. coronary vascular disease. In conclusion, our study strengthens the support for MMP12 as a causal factor in large-artery atherosclerotic stroke and highlights its role in macrophage invasion and elastin degradation.
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